Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
Hong Kong Pharmaceutical stocks generally rose. As of press time, Cinda bio rose nearly 6%, Sansheng pharmaceutical, Baiji Shenzhou, kangxinuo and Chinese traditional medicine rose nearly 5%, and yimingkant rose nearly 4%.
This text is a result of machine translation.
Related companies：
In-depth
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Jun 10, 2022 09:48 PM
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Briefing Jun 10, 2022 07:17 PM
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
Healthcare
CNMPA Approved World's First Inhaled COVID-19 Vaccine Mist
The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
Sep 06, 2022 11:48 AM
Healthcare
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Briefing Apr 28, 2022 09:59 AM
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth